Tonix Pharmaceuticals Holding Corp. announced its financial results for Q4 and full year 2025, highlighting a successful launch of TONMYA for fibromyalgia, with over 4,200 prescriptions written. The company also reported $207.6 million in cash as of year-end 2025, indicating strong liquidity.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.